Clinical Trial Update: Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial of bevacizumab and ixabepilone in advanced or metastatic non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Ixabepilone (ixabepilone)

Snippet

Sponsor: Providence Health & Services | Conditions: Non-squamous Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED